Biosplice Therapeutics

{{Short description|American biopharmaceutical company}}

{{DISPLAYTITLE:Biosplice Therapeutics}}

{{Infobox company

| name = Biosplice Therapeutics

| logo =

| type = Privately held company

| industry = Regenerative medicine

| fate = renamed from Samumed

| predecessor =

| successor =

| founded = {{Start date and age|2008}} in San Diego, USA

| founder = Osman Kibar

| defunct =

| hq_location_city = San Diego, USA

| hq_location_country =

| area_served =

| key_people =

| products =

| owner =

| num_employees =

| num_employees_year =

| parent =

| website = {{URL|https://www.biosplice.com}}

}}

Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California.{{Cite web |last= |date=2023-08-16 |title=Small-molecule therapeutics using Biosplice Therapeutics |url=https://www.businessoutreach.in/therapeutics-using-biosplice-therapeutics/ |access-date=2024-07-06 |website=Business Outreach}} It was founded in 2008 by Osman Kibar.[https://www.forbes.com/sites/matthewherper/2016/04/13/the-god-pill/#51874b9d5757 "Forbes Profile: Osman Kibar"], "Forbes"

Samumed's products in development target novel components of the Wnt signaling pathway.Herper, Matthew.[https://www.forbes.com/sites/matthewherper/2016/04/13/the-god-pill/#51874b9d5757 "Cure Baldness? Heal Arthritis? Erase Wrinkles? An Unknown Billionaire's Quest To Reverse Aging"], "Forbes", May 10, 2016Ramsey, Lydia. [http://www.businessinsider.com/samumed-wants-to-regenerate-hair-bone-cartilage-2017-3 "A $12 billion startup you've probably never heard wants to cure baldness and smooth out your wrinkles"], "Business Insider", April 2, 2017Lee, Yoolim. [https://www.bloomberg.com/news/articles/2017-02-09/eternal-youth-is-the-next-big-bet-for-singapore-venture-capitalist "Eternal Youth Is the Next Big Bet for Singapore Venture Capitalist"], "Bloomberg", February 9, 2017 The company focuses on potential treatments for several diseases; its osteoarthritis program is its most advanced.Jackson, Mandy. [https://scrip.pharmaintelligence.informa.com/SC099838/ACR-Notebook-Lillys-Baricitinib-Differentiates-On-Pain-Ironwoods-Duzallo-Progress-Corbus-Nears-Phase-III "ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III"], "Informa Scrip", November 8, 2017"